Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
Statement: Zantac (ranitidine) litigation
MDL Court has dismissed all cases alleging the five remaining cancers in the MDL
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
Regulatory submissions based on the trial results are planned for the first half of 2023.
European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
Application includes data from key phase III trials, including the pivotal MOMENTUM trial.
New global survey reveals opportunities to address organ damage risk with people living with lupus earlier in the course of their disease
Survey examined healthcare professional approaches to preventing organ damage
GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation
GSK has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf)
GSK tops Access to Medicine Index (ATMI) for eighth consecutive time
Company also announces £100 million investment over next ten years to support access initiatives in lower income countries
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future.
GSK provides an update on Zejula (niraparib) US prescribing information
Zejula is an oral, once-daily PARP inhibitor currently being evaluated in multiple pivotal trials.
Positive data for bepirovirsen from B-Clear phase IIb trial presented at American Association for the Study of Liver Diseases’ Meeting with simultaneous publication in the New England Journal of Medicine
Phase III trial evaluating bepirovirsen to start in H1 2023.
GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma
DREAMM-3 did not meet its primary endpoint of progression-free survival (PFS)
EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee
Gepotidacin could be the first new novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years
GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA
The US FDA has accepted a Biologics License Application and granted Priority Review for its RSV older adult vaccine candidate.
GSK delivers strong Q3 2022 sales of £7.8 billion +18% AER, +9% CER and Total EPS 255.9p +>100% AER, +>100% CER; Adjusted EPS of 46.9p +25% AER, +11% CER
Strong commercial execution drives continued sales growth across Specialty Medicines, Vaccines and General Medicines
European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention
The marketing application is based on results from the HPTN 083 and 084 phase IIb/III studies.
GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment
The vaccine was well tolerated with a favourable safety profile.
GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis
Full results from the ContRAst phase III programme will be submitted for publication in 2023.
GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD
Daprodustat was studied in the ASCEND phase III clinical trial programme.
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb
GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate
The proposed indication is for adults aged 60 years and above to prevent lower respiratory tract diseases (LRTD) caused by RSV.
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
The ZOSTER-049 extension study shows that Shingrix can provide at least a decade of protection against shingles after initial vaccination